Teladoc Inc (TDOC)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NYSE
Market Cap: $1.60B
Last updated: Nov 17, 2026 at 11:06 AM ET
Teladoc Inc (TDOC) Valuation Multiples
Teladoc (TDOC) trades at 0.6x sales and 1.2x book value. Its P/S of 0.6x is below its 5-year median of 0.8x. Its forward P/E is 303.0x.
Current Multiples
Its enterprise value is 8.4x its EBITDA. Its free cash flow yield is 8.7%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 303.0x |
| Price to sales | 0.6x |
| Price to book | 1.2x |
| EV/EBITDA | 8.4x |
| Price to FCF | 11.5x |
| EV/FCF | 12.8x |
| PEG | N/A |
| FCF yield | 8.7% |
Historical Medians
Against its 10-year medians, its P/S is 91.4% below 7.0x and its P/B is 29.4% below 1.7x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 0.6x | 0.8x | 7.0x |
| P/B | 1.2x | 1.0x | 1.7x |
Valuation History
Over the 10 year ends shown, its P/S ranged from 0.5x in 2025 to 16.6x in 2020. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $7.00 | 0.5x | 0.9x |
| 2024 | $9.09 | 0.6x | 1.1x |
| 2023 | $21.55 | 1.4x | 1.5x |
| 2022 | $23.65 | 1.6x | 1.7x |
| 2021 | $91.82 | 7.1x | 0.9x |
| 2020 | $199.96 | 16.6x | 1.6x |
| 2019 | $83.72 | 10.9x | 6.0x |
| 2018 | $49.57 | 7.8x | 3.4x |
| 2017 | $34.85 | 8.3x | 3.6x |
| 2016 | $16.50 | 5.9x | 3.7x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TDOC
What is TDOC's forward P/E ratio?
Teladoc has a forward P/E ratio of 303.0x.
Is TDOC stock overvalued?
GNG's valuation label for TDOC is Fairly valued.
What is TDOC's price to sales ratio?
Teladoc has a price to sales ratio of 0.6x.
TDOC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors